Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

H2 Pharma Offloads Minority Interest To Private Equity

H2 Pharma, which specializes in both generic and OTC liquid formulations, is looking to climb to the next level after receiving an equity investment from Ardian.

Financing Companies

Hikma Eyes Another Hybrid Injectable With Arecor

London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.

Deals Companies

Zentiva Continues European Endeavors With Greek Partnership

Zentiva has struck a new partnership to expand its already significant operations in Europe, this time in Greece with local firm Lavipharm.

Deals Companies
See All

Deals Explore this Topic

Set Alert for Deals

Hikma Eyes Another Hybrid Injectable With Arecor

London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.

Deals Companies

Zentiva Continues European Endeavors With Greek Partnership

Zentiva has struck a new partnership to expand its already significant operations in Europe, this time in Greece with local firm Lavipharm.

Deals Companies

Siegfried Buys Two Spanish Sites From Novartis

After making several targeted investments aimed at enhancing its global production network, Siegfried has announced the acquisition of two manufacturing sites from Novartis in Spain. With this acquisition, the Swiss contract development and manufacturing organization is looking to create opportunities for profitable growth and achieve “critical size.”

Deals Manufacturing
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

Shilpa Hit With FDA Warning Letter

India’s Shilpa Medicare has received a warning letter from the US FDA for its finished dosage formulation facility in Jadcherla, Telangana. The company has insisted that supplies from the facility will not be disrupted while it engages with the FDA to resolve the issues.

FDA Manufacturing

US FDA Launches Quality Maturity Pilot Program

High ratings on factors like quality culture could yield post-approval change flexibility for participating drug product and API manufacturing facilities.

Manufacturing Quality

Siegfried Buys Two Spanish Sites From Novartis

After making several targeted investments aimed at enhancing its global production network, Siegfried has announced the acquisition of two manufacturing sites from Novartis in Spain. With this acquisition, the Swiss contract development and manufacturing organization is looking to create opportunities for profitable growth and achieve “critical size.”

Deals Manufacturing
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Roche’s Biosimilar Losses Could Be Closer To CHF5bn

Roche entered the year with a projected hit to revenues from multi-source biosimilar competition to its three leading biologics. However, the number was increased at the half-year mark and could be set to ratchet up further, according to management.

Biosimilars Sales & Earnings

Generics Industry Counts Cost Of Stormy Second Quarter

As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.

Coronavirus COVID-19 Generic Drugs

Aspen Says Reshaping Has Been ‘Painful’ But Is Over Now

Fresh from announcing the €642m ($762m) divestment of its Thrombosis business in Europe to Mylan, Aspen Pharmacare management walked investors through its full-year earnings, explaining in detail the company’s ambitions to focus on emerging markets.

Sales & Earnings Strategy
See All

People Explore this Topic

Set Alert for People

Hyloris Bolsters Management Team Following Approvals

Belgian value-added medicines specialist Hyloris Pharmaceuticals has bolstered its management team with the appointment of a chief operating officer, shortly after receiving eight European approvals for its Maxigesic IV pain treatment.

Appointments Strategy

Stada Names New Global Development Head

Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.

Appointments Strategy

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.

Appointments India
See All
UsernamePublicRestriction

Register